Compare HUN & GH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HUN | GH |
|---|---|---|
| Founded | 1970 | 2011 |
| Country | United States | United States |
| Employees | N/A | 2021 |
| Industry | Major Chemicals | Medical Specialities |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 13.2B |
| IPO Year | 2005 | 2018 |
| Metric | HUN | GH |
|---|---|---|
| Price | $10.92 | $112.15 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 11 | 21 |
| Target Price | $10.23 | ★ $99.48 |
| AVG Volume (30 Days) | ★ 4.2M | 1.8M |
| Earning Date | 02-17-2026 | 02-19-2026 |
| Dividend Yield | ★ 3.34% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $5,780,000,000.00 | $902,569,000.00 |
| Revenue This Year | N/A | $35.00 |
| Revenue Next Year | $3.31 | $26.80 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 30.38 |
| 52 Week Low | $7.30 | $33.75 |
| 52 Week High | $18.53 | $112.43 |
| Indicator | HUN | GH |
|---|---|---|
| Relative Strength Index (RSI) | 68.27 | 70.14 |
| Support Level | $9.90 | $97.31 |
| Resistance Level | $10.47 | $104.75 |
| Average True Range (ATR) | 0.38 | 3.83 |
| MACD | 0.02 | 0.26 |
| Stochastic Oscillator | 82.67 | 99.25 |
Huntsman Corp is a USA-based manufacturer of differentiated organic chemical products. Its product portfolio comprises Methyl diphenyl diisocyanate (MDI), Amines, Maleic anhydride, and Epoxy-based polymer formulations. The company's products are used in adhesives, aerospace, automotive, and construction products, among others. Its operating segments are Polyurethanes, Performance Products, and Materials. It derives the majority of its revenue from the Polyurethanes segment, which includes MDI, polyols, TPU (thermoplastic polyurethane), and other polyurethane-related products. Its geographical segments are the United States & Canada, Europe, Asia-Pacific, and the Rest of the world.
Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced-stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant Omni, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.